Apomorphine subcutaneous - Neuroderm

Drug Profile

Apomorphine subcutaneous - Neuroderm

Alternative Names: ND-0701

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator NeuroDerm
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 30 Mar 2017 NeuroDerm plans to meet EU regulatory authorities in the first half of 2017
  • 30 Mar 2017 NeuroDerm plans to initiate a follow-on pharmacokinetics trial for in 2H 2017
  • 02 Dec 2016 Top-line pharmacokinetics and adverse events data from the pilot bioequivalence trial (Trial 101) in healthy volunteers released by NeuroDerm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top